From Siemens Medical Systems;
the MAGNETOM Rhapsody™. This open MRI system offers the proven image quality of 1.0 Tesla. In addition to the resulting broad range of applications, the open magnet of the high field system MAGNETOM Rhapsodyâ„¢ facilitates examination of claustrophobic and pediatric patients. And the system allows for expanded interventional applications.

From Siemens Medical Systems;
while older navigator techniques take up to 40 minutes to create, the high performance of the MAGNETOM Sonata system enables 'complete examinations in less than 15 minutes'. It creates a new standard of diagnostic confidence and moves Cardiac MR from the research setting into routine clinical practice.

From Siemens Medical Systems;
with the introduction of this system, it is possible to perform contrast MR angiography for abdominal, thoracic and neck vessels from the origins to the circle of Willis. The system also has many newer features including functional imaging, spectroscopy, advanced body, ortho- and neuroimaging.

From Siemens Medical Systems;
70 cm + 125 cm + 1.5T and Tim - a combination never seen before in MRI ... MAGNETOM Espree™s unique open bore design can accommodate more types of patients than other 1.5T systems on the market today, in particular the growing population of obese patients. The power of 1.5T combined with Tim technology boosts signal to noise, which is necessary to adequately image obese patients.

MS-325 is the formerly code name of gadofosveset trisodium (new trade name Vasovist). MS-325 belongs to a new class of blood pool agents for magnetic resonance angiography (MRA) to diagnose vascular disease. Gadofosveset trisodium has ten times the signal-enhancing power of existing contrast agents as well as prolonged retention in the blood. This enables the rapid acquisition of high resolution MRA's using standard MRI machines.
Gadofosveset trisodium, which is gadolinium-based, stays in the blood stream as a result of transient binding to albumin. Albumin binding offers an additional benefit beyond localization in the blood pool. The contrast agent begins to spin much more slowly, at the rate albumin spins, causing a relaxivity gain that produces a substantially brighter signal than would be possible with freely circulating gadolinium. MS-325 is an intravascular contrast agent intended for use in MRI as an aid in diagnosing aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease (PVD) or abdominal aortic aneurysm (AAA).
Currently clinical trials completed for peripheral vascular disease and coronary artery disease. Additional trials are also being conducted to evaluate MS-325 as an aid in diagnosing breast cancer and suggested that it might be feasible to combine the use of MS-325, injected during peak stress, with delayed high-resolution imaging to identify myocardial perfusion defects.
Vasovist (MS-325) would compete with the contrast agents Ferumoxytol (Code 7228) from AMAG Pharmaceuticals, Inc. and NC100150 Injection from Nycomed Amersham, but their further development is uncertain.
Partners in development: EPIX Pharmaceuticals, Inc., Mallinckrodt Inc., and Bayer Schering Pharma AG. Bayer Schering Pharma has the worldwide marketing rights for the product.
Formerly known under the Mallinckrodt trademark name, AngioMARK®.

See also Classifications, Characteristics, etc.